This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2002 Nov 26;59(10):1480-1.

doi: 10.1212/wnl.59.10.1480.

When marketing and science intersect: do patients with MS benefit?

Fred D Lublin¹

Affiliations

PMID: 12451185
DOI: 10.1212/wnl.59.10.1480

Comment

When marketing and science intersect: do patients with MS benefit?

Fred D Lublin. Neurology. 2002.

. 2002 Nov 26;59(10):1480-1.

doi: 10.1212/wnl.59.10.1480.

Author

Fred D Lublin¹

Affiliation

¹ Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029-6574, USA. Fred.Lublin@mssm.edu

PMID: 12451185
DOI: 10.1212/wnl.59.10.1480

No abstract available

PubMed Disclaimer

Comment in

Needed in MS: evidence, not EVIDENCE.
Kieburtz K, McDermott M. Kieburtz K, et al. Neurology. 2002 Nov 26;59(10):1482-3. doi: 10.1212/wnl.59.10.1482. Neurology. 2002. PMID: 12451186 No abstract available.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial.
Byrne E. Byrne E. Neurology. 2003 Jun 10;60(11):1872; author reply 1872-3. Neurology. 2003. PMID: 12796564 Clinical Trial. No abstract available.

Comment on

Needed in MS: evidence, not EVIDENCE.
Kieburtz K, McDermott M. Kieburtz K, et al. Neurology. 2002 Nov 26;59(10):1482-3. doi: 10.1212/wnl.59.10.1482. Neurology. 2002. PMID: 12451186 No abstract available.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B; EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Panitch H, et al. Neurology. 2002 Nov 26;59(10):1496-506. doi: 10.1212/01.wnl.0000034080.43681.da. Neurology. 2002. PMID: 12451188 Clinical Trial.
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators. Clanet M, et al. Neurology. 2002 Nov 26;59(10):1507-17. doi: 10.1212/01.wnl.0000032256.35561.d6. Neurology. 2002. PMID: 12451189 Clinical Trial.

Similar articles

Editorial: Licensing and Use of New Therapies in MS: Where Are We Going?
Hurwitz B. Hurwitz B. Int MS J. 2005 Aug;12(2):39-41. Int MS J. 2005. PMID: 16417813 No abstract available.
From the Food and Drug Administration.
Nightingale SL. Nightingale SL. JAMA. 1993 Oct 13;270(14):1672. doi: 10.1001/jama.270.14.1672. JAMA. 1993. PMID: 8411485 No abstract available.
Berlex continues legal challenge to FDA over MS drug.
Glaser V. Glaser V. Nat Biotechnol. 1996 Jul;14(7):811-2. doi: 10.1038/nbt0796-811b. Nat Biotechnol. 1996. PMID: 9630997 No abstract available.
Intravenous immunoglobulin and multiple sclerosis.
Achiron A, Miron S. Achiron A, et al. Clin Rev Allergy Immunol. 2005 Dec;29(3):247-54. doi: 10.1385/CRIAI:29:3:247. Clin Rev Allergy Immunol. 2005. PMID: 16391400 Review.
[Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
Demina TL, Khachanova NV, Davydovskaia MV, Popova NF, Gusev EI. Demina TL, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):24-6. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID: 18567192 Review. Russian. No abstract available.

See all similar articles

Cited by

Multiple sclerosis therapy: an update on recently finished trials.
Kleinschnitz C, Meuth SG, Stüve O, Kieseier B, Wiendl H. Kleinschnitz C, et al. J Neurol. 2007 Nov;254(11):1473-90. doi: 10.1007/s00415-007-0684-7. Epub 2007 Nov 15. J Neurol. 2007. PMID: 18004638 Review.
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC. Warnke C, et al. Drug Des Devel Ther. 2010 Jul 21;4:117-26. doi: 10.2147/dddt.s6627. Drug Des Devel Ther. 2010. PMID: 20689698 Free PMC article. Review.
[Interferon β for multiple sclerosis. How much is good enough?].
Warnke C, Leussink VI, Kieseier BC, Hartung HP. Warnke C, et al. Nervenarzt. 2010 Dec;81(12):1476-82. doi: 10.1007/s00115-010-3017-5. Nervenarzt. 2010. PMID: 21104222 Review. German.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information